Welcome to our dedicated page for Inhibikase Therapeutics SEC filings (Ticker: IKT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Inhibikase Therapeutics, Inc. filings document the disclosure record for a Nasdaq-listed clinical-stage pharmaceutical company developing IKT-001 for pulmonary arterial hypertension. Form 8-K reports cover operating and financial results, Regulation FD materials, clinical and regulatory updates for IMPROVE-PAH, and exhibits furnished with company press releases and corporate presentations.
Proxy and annual-meeting filings address board elections, auditor ratification, equity incentive plan amendments, executive compensation and shareholder voting results. Other disclosures describe the company's common stock, Nasdaq listing, inducement equity awards, material agreements, and capital-structure matters involving common stock and warrant securities.
Perceptive Advisors LLC and its affiliates report beneficial ownership of 12,816,643 shares of Inhibikase Therapeutics common stock, representing 9.99% of the class. This total includes shares underlying pre-funded and common warrants held by Perceptive Life Sciences Master Fund, Ltd., subject to a 9.99% ownership cap on warrant exercise.
The ownership percentage is based on 120,899,650 shares outstanding as of a recent prospectus supplement, and reflects shared voting and dispositive power among Perceptive Advisors, Joseph Edelman, and the Master Fund. The group certifies the holdings are not for the purpose of changing or influencing control of Inhibikase.
Nantahala Capital Management, LLC and principals Wilmot B. Harkey and Daniel Mack report their beneficial ownership of Inhibikase Therapeutics common stock on an amended Schedule 13G. As of December 31, 2025, they may be deemed to beneficially own 7,037,916 shares, or 5.68% of the outstanding common stock.
This total includes 3,108,624 shares that could be acquired within sixty days through warrant exercises. The reporting persons state they share voting and dispositive power over these shares and certify the holdings are in the ordinary course of business, not for the purpose of changing or influencing control.
Sands Capital Life Sciences Pulse Fund II, L.P. and related entities report a 10.8% beneficial stake in Inhibikase Therapeutics, Inc. They collectively hold 13,018,965 shares of common stock, based on 120,899,650 shares outstanding as of November 20, 2025, as referenced in the issuer's prospectus supplement.
The filing explains that this ownership is attributed to Sands Capital Life Sciences Pulse Fund II, its investment manager Sands Capital Alternatives, LLC, and Frank M. Sands, who has ultimate voting and investment power. It also describes additional Series A-1 and Series B-1 warrants held by the fund that are not counted as beneficially owned because they are not exercisable within 60 days and are subject to a 19.99% ownership cap after exercise.
Inhibikase Therapeutics, Inc. reported a new stock option grant to its Chief Executive Officer and director, Mark T. Iwicki. On January 5, 2026, he was awarded a stock option covering 4,982,706 shares of common stock at an exercise price of $2.01 per share.
The option is described as a right to buy common stock and had no purchase price at grant. It becomes exercisable in 36 equal monthly installments starting on January 5, 2026, and each vesting installment depends on his continued employment through that vesting date. The option relates to 4,982,706 underlying common shares and is scheduled to expire on January 5, 2036, if not exercised earlier.
Inhibikase Therapeutics reported that President & Head of R&D Cabell Christopher received a grant of stock options on January 5, 2026. The award covers 900,117 stock options, each with an exercise price of $2.01 per share, giving the right to buy common stock. According to the disclosure, the options vest in 36 equal monthly installments starting January 5, 2026, and vesting is conditioned on Christopher’s continued employment through each vesting date. Following this grant, Christopher beneficially holds 900,117 derivative securities directly.
Inhibikase Therapeutics reported an insider equity award for its Chief Financial Officer, David McIntyre. He received a stock option grant covering 986,319 shares of common stock at an exercise price of $2.01 per share on January 5, 2026. The option was granted at a cost of $0 on the grant date, so no shares were bought or sold in this transaction.
The option vests and becomes exercisable in 36 equal monthly installments starting on January 5, 2026, and is scheduled to expire on January 5, 2036. Following this grant, McIntyre beneficially owns derivative securities representing 986,319 option rights held directly.
Sands Capital Life Sciences Pulse Fund II, L.P. filed a Form 4 reporting a purchase of 2,068,965 shares of Inhibikase Therapeutics, Inc. (IKT) common stock in an underwritten public offering on 11/21/2025 at $1.45 per share. Following this transaction, the fund reports holding 13,018,965 shares directly.
The filing is made jointly by related entities, including Sands Capital Alternatives, LLC and affiliates, with the reporting persons identified as a director and 10% owner of IKT. Footnotes explain that additional Series A-1 and Series B-1 warrants to purchase 5,475,000 and 10,068,120 shares of common stock, respectively, are not included in the reported beneficial ownership because they are not exercisable within 60 days and are subject to a 19.99% beneficial ownership cap.
Inhibikase Therapeutics announced an underwritten public offering of 46,091,739 shares of common stock and pre-funded warrants to purchase up to 22,873,779 additional shares. Each share is priced at $1.45 and each pre-funded warrant at $1.449, with an exercise price of $0.001 per share. The company granted underwriters a 30-day option to buy up to 10,344,827 more shares at the public offering price, less underwriting discounts and commissions.
Inhibikase expects net proceeds of approximately $93.6 million, or $107.7 million if the underwriters’ option is fully exercised. The pre-funded warrants are immediately exercisable and include ownership caps generally at 4.99% or 9.99%, adjustable up to 19.99% with notice. The company also amended outstanding Series A-1 and Series B-1 warrants issued in 2024 to reflect its plan to advance IKT-001 to a global pivotal Phase 3 trial in pulmonary arterial hypertension.
Inhibikase Therapeutics, Inc. is conducting a primary offering of 46,091,739 shares of common stock and pre-funded warrants to purchase up to 22,873,779 shares of common stock at $1.45 and $1.449, respectively. The deal is expected to generate gross proceeds of about $99,997,127, with approximately $93.6 million in net proceeds after underwriting fees and expenses. The company plans to use the cash, together with existing funds, mainly to advance its lead PAH candidate IKT-001 through an adaptive Phase 3 program and for broader R&D, potential acquisitions, and general corporate purposes, which it estimates will fund operations into 2029.
Inhibikase Therapeutics has filed a prospectus supplement for a public offering of common stock and, for some investors, pre-funded warrants that are exercisable for common shares at an exercise price of $0.001 per share and do not expire, subject to ownership limits. The warrants are not expected to trade on an exchange.
The company is a clinical-stage pharma focused on cardiopulmonary disease, with lead candidate IKT-001, an oral prodrug of imatinib mesylate for pulmonary arterial hypertension (PAH). IKT-001 has shown bioequivalence to imatinib doses used in prior PAH studies, and the FDA has indicated the 505(b)(2) pathway is appropriate. An adaptive Phase 3 trial in PAH, IMPROVE-PAH, is expected to start in the first quarter of 2026.
As of September 30, 2025, Inhibikase had 74,807,911 common shares outstanding and $77.3 million in cash, cash equivalents and marketable securities. The company previously raised approximately $110 million in an October 2024 private placement to support IKT-001 and holds U.S. patent protection for IKT-001 into 2033, with possible method-of-use protection to 2044. Net proceeds from this offering are expected to fund IKT-001 development, other R&D, possible acquisitions and general corporate purposes, but will cause dilution to new investors. In connection with this deal, the existing ATM prospectus under the $300 million shelf registration has been terminated, though the related sales agreement remains in effect.